Full title: A Phase 1, Open-label, Multicenter, Dose-escalation and Cohort Expansion Study of OKN4395, a Triple Antagonist of EP2, EP4, and DP1 Prostanoid Receptors, as Monotherapy and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors
Age: 18+
Phase: 1
Locations:
- Glasgow – The Beatson Hospital
- London – University College London Hospital
- Manchester – The Christie Hospital
- Oxford – Churchill Hospital
Brief summary:
INVOKE is a phase 1 international study testing a new drug called OKN4395. Researchers want to understand its safety and side effects in people with solid tumours sarcoma. The study is looking how well the drug works on its own and together with the immunotherapy pembrolizumab. It is open to patients hose sarcoma has not responded to standard treatments.
More information can be found at clinicaltrials.gov
To find out more about this trial and whether you could take part, talk to your clinical team.
